This is a preview of subscription content, log in via an institution to check access.
Notes
2017 Japanese yen
Reference
Lertjanyakun V, et al. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan. PharmacoEconomics : 30 Apr 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0660-3
Rights and permissions
About this article
Cite this article
Toremifene cost effective in metastatic breast cancer. PharmacoEcon Outcomes News 802, 32 (2018). https://doi.org/10.1007/s40274-018-4923-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4923-1